Now showing items 1888-1907 of 3103

    • Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. 

      Ameratunga, M; Chénard-Poirier, M; Moreno Candilejo, I; Pedregal, M; Lui, A; Dolling, D; Aversa, C; Ingles Garces, A; Ang, JE; Banerji, U; Kaye, S; Gan, H; Doger, B; Moreno, V; de Bono, J; Lopez, J (2018-01)
      BACKGROUND: Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought ...
    • New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders 

      Matutes, E (2002-03)
      Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative ...
    • A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity 

      Mann, J; Baron, A; Opoku-Boahen, Y; Johansson, E; Parkinson, G; Kelland, LR; Neidle, S (2001-01-18)
      The synthesis and evaluation of the novel head-to-head bisbenzimidazole compound 2,2-bis[4’-(3 “ -dimethylamino- 1 “ -propyloxy)phenyl]-5,5-bi-1H-benzimidazole is described. An X-ray crystallographic study of a complex ...
    • New insights into the families of PLC enzymes: looking back and going forward 

      Katan, M (Portland Press Limited, 2005)
      A study in this issue of the Biochemical Journal by Harden and colleagues, in association with one published in the Biochemical Journal very recently [Hwang, Oh, Shin, Kim, Ryu and Suh (2005) Biochem. J. 389, 181–186], ...
    • New method for the preparation of 3 ‘- and 2 ‘-O-phosphoramidites of 2 ‘- and 3 ‘-difluoromethyluridine derivatives 

      Serafinowski, PJ; Brown, CA (2002)
      Hydrogenation of 2-deoxy-2’-difluoromethylene-5’-O-dimethoxytrityluridine (1) and 3’-deoxy-3’-difluoromethylene-5’-O-dimethoxytrityluridine (7), gave the corresponding 2- and 3’-difluoromethyluridine derivatives 2a and 8a. ...
    • New Model for Estimating Glomerular Filtration Rate in Patients With Cancer 

      Janowitz, T; Williams, EH; Marshall, A; Ainsworth, N; Thomas, PB; Sammut, SJ; Shepherd, S; White, J; Mark, PB; Lynch, AG; Jodrell, DI; Tavaré, S; Earl, H (American Society of Clinical Oncology (ASCO), 2017-08-20)
    • New tricks for an old dog: Brf2-dependent RNA Polymerase III transcription in oxidative stress and cancer. 

      Gouge, J; Vannini, A (2018)
      Here, we discuss the role of Brf2, an RNA Polymerase III core transcription factor, as a master switch of the oxidative stress response. We highlight the interplay of Brf2 with the Nrf2/Keap1 pathway, as well as the role ...
    • Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. 

      Henderson, DR; de Souza, NM; Thomas, K; Riches, SF; Morgan, VA; Sohaib, SA; Dearnaley, DP; Parker, CC; van As, NJ (2016-06)
      In active surveillance (AS) for prostate cancer there are few data on long-term outcomes associated with novel imaging markers.To determine long-term outcomes with respect to the apparent diffusion coefficient (ADC) derived ...
    • Nintedanib in ovarian cancer. 

      Khalique, S; Banerjee, S (2017-09)
      INTRODUCTION: Advanced ovarian cancer remains an unmet clinical need. Angiogenesis is considered a therapeutic target in ovarian cancer, with bevacizumab, a monoclonal antibody against VEGF, being the first drug to show a ...
    • Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. 

      Popat, S; Mellemgaard, A; Reck, M; Hastedt, C; Griebsch, I (2017-06)
      PATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer. RESULTS: ...
    • Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. 

      Grosso, F; Steele, N; Novello, S; Nowak, AK; Popat, S; Greillier, L; John, T; Leighl, NB; Reck, M; Taylor, P; Planchard, D; Sørensen, JB; Socinski, MA; von Wangenheim, U; Loembé, AB; Barrueco, J; Morsli, N; Scagliotti, G (2017-11-01)
      Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results ...
    • Nipple sparing versus skin sparing mastectomy: a systematic review protocol. 

      Agha, RA; Wellstead, G; Sagoo, H; Al Omran, Y; Barai, I; Rajmohan, S; Fowler, AJ; Orgill, DP; Rusby, JE (2016-05-20)
      INTRODUCTION: Breast cancer has a lifetime incidence of one in eight women. Over the past three decades there has been a move towards breast conservation and a focus on aesthetic outcomes while maintaining oncological ...
    • Nivolumab and Ipilimumab in Advanced Melanoma. 

      Wolchok, JD; Rollin, L; Larkin, J (2017-12-21)
    • Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. 

      Long, GV; Weber, JS; Larkin, J; Atkinson, V; Grob, J-J; Schadendorf, D; Dummer, R; Robert, C; Márquez-Rodas, I; McNeil, C; Schmidt, H; Briscoe, K; Baurain, J-F; Hodi, FS; Wolchok, JD (2017-11-01)
      Importance: Immune checkpoint inhibitors have demonstrated atypical response patterns, which may not be fully captured by conventional response criteria. There is a need to better understand the potential benefit of continued ...
    • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, K; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Iglesias Docampo, LC; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Monga, M; Lynch, M; Geese, WJ; Kopit, J; Shaw, JW; Gillison, ML (2016-11-10)
      BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 ...
    • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. 

      Harrington, KJ; Ferris, RL; Blumenschein, G; Colevas, AD; Fayette, J; Licitra, L; Kasper, S; Even, C; Vokes, EE; Worden, F; Saba, NF; Kiyota, N; Haddad, R; Tahara, M; Grünwald, V; Shaw, JW; Monga, M; Lynch, M; Taylor, F; DeRosa, M; Morrissey, L; Cocks, K; Gillison, ML; Guigay, J (2017-08)
      BACKGROUND: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient ...
    • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Docampo, LCI; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Lynch, M; Jayaprakash, V; Li, L; Gillison, ML (2018-06)
      OBJECTIVES: We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory ...
    • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 

      Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; Aben, KK; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Apicella, C; Arndt, V; Arnold, N; Arun, BK; Arver, B; Ashworth, A; Baglietto, L; Balleine, R; Bandera, EV; Barrowdale, D; Bean, YT; Beckmann, L; Beckmann, MW; Benitez, J; Berger, A; Berger, R; Beuselinck, B; Bisogna, M; Bjorge, L; Blomqvist, C; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Brand, JS; Brauch, H; Brenner, H; Brinton, L; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Brüning, T; Budzilowska, A; Bunker, CH; Burwinkel, B; Butzow, R; Buys, SS; Caligo, MA; Campbell, I; Carter, J; Chang-Claude, J; Chanock, SJ; Claes, KB; Collée, JM; Cook, LS; Couch, FJ; Cox, A; Cramer, D; Cross, SS; Cunningham, JM; Cybulski, C; Czene, K; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; de la Hoya, M; deFazio, A; Dennis, J; Devilee, P; Dicks, EM; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Silva, IS; du Bois, A; Dumont, M; Dunning, AM; Duran, M; Easton, DF; Eccles, D; Edwards, RP; Ehrencrona, H; Ejlertsen, B; Ekici, AB; Ellis, SD; Engel, C; Eriksson, M; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Fontaine, A; Fortuzzi, S; Fostira, F; Fridley, BL; Friebel, T; Friedman, E; Friel, G; Frost, D; Garber, J; García-Closas, M; Gayther, SA; Gentry-Maharaj, A; Gerdes, AM; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goodman, MT; Gore, M; Greene, MH; Grip, M; Gronwald, J; Gschwantler Kaulich, D; Guénel, P; Guzman, SR; Haeberle, L; Haiman, CA; Hall, P; Halverson, SL; Hamann, U; Hansen, TV; Harter, P; Hartikainen, JM; Healey, S; Hein, A; Heitz, F; Henderson, BE; Herzog, J; T Hildebrandt, MA; Høgdall, CK; Høgdall, E; Hogervorst, FB; Hopper, JL; Humphreys, K; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; Janavicius, R; Jaworska, K; Jensen, A; Jensen, UB; Johnson, N; Jukkola-Vuorinen, A; Kabisch, M; Karlan, BY; Kataja, V; Kauff, N; Kelemen, LE; Kerin, MJ; Kiemeney, LA; Kjaer, SK; Knight, JA; Knol-Bout, JP; Konstantopoulou, I; Kosma, VM; Krakstad, C; Kristensen, V; Kuchenbaecker, KB; Kupryjanczyk, J; Laitman, Y; Lambrechts, D; Lambrechts, S; Larson, MC; Lasa, A; Laurent-Puig, P; Lazaro, C; Le, ND; Le Marchand, L; Leminen, A; Lester, J; Levine, DA; Li, J; Liang, D; Lindblom, A; Lindor, N; Lissowska, J; Long, J; Lu, KH; Lubinski, J; Lundvall, L; Lurie, G; Mai, PL; Mannermaa, A; Margolin, S; Mariette, F; Marme, F; Martens, JW; Massuger, LF; Maugard, C; Mazoyer, S; McGuffog, L; McGuire, V; McLean, C; McNeish, I; Meindl, A; Menegaux, F; Menéndez, P; Menkiszak, J; Menon, U; Mensenkamp, AR; Miller, N; Milne, RL; Modugno, F; Montagna, M; Moysich, KB; Müller, H; Mulligan, AM; Muranen, TA; Narod, SA; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nielsen, SF; Nordestgaard, BG; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olson, SH; Oosterwijk, JC; Orlow, I; Orr, N; Orsulic, S; Osorio, A; Ottini, L; Paul, J; Pearce, CL; Pedersen, IS; Peissel, B; Pejovic, T; Pelttari, LM; Perkins, J; Permuth-Wey, J; Peterlongo, P; Peto, J; Phelan, CM; Phillips, KA; Piedmonte, M; Pike, MC; Platte, R; Plisiecka-Halasa, J; Poole, EM; Poppe, B; Pylkäs, K; Radice, P; Ramus, SJ; Rebbeck, TR; Reed, MW; Rennert, G; Risch, HA; Robson, M; Rodriguez, GC; Romero, A; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, I; Salani, R; Salvesen, HB; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schrauder, MG; Schumacher, F; Schwaab, I; Scuvera, G; Sellers, TA; Severi, G; Seynaeve, CM; Shah, M; Shrubsole, M; Siddiqui, N; Sieh, W; Simard, J; Singer, CF; Sinilnikova, OM; Smeets, D; Sohn, C; Soller, M; Song, H; Soucy, P; Southey, MC; Stegmaier, C; Stoppa-Lyonnet, D; Sucheston, L; Swerdlow, A; Tangen, IL; Tea, MK; Teixeira, MR; Terry, KL; Terry, MB; Thomassen, M; Thompson, PJ; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RA; Tomlinson, I; Torres, D; Truong, T; Tsimiklis, H; Tung, N; Tworoger, SS; Tyrer, JP; Vachon, CM; Van 't Veer, LJ; van Altena, AM; Van Asperen, CJ; van den Berg, D; van den Ouweland, AM; van Doorn, HC; Van Nieuwenhuysen, E; van Rensburg, EJ; Vergote, I; Verhoef, S; Vierkant, RA; Vijai, J; Vitonis, AF; von Wachenfeldt, A; Walsh, C; Wang, Q; Wang-Gohrke, S; Wappenschmidt, B; Weischer, M; Weitzel, JN; Weltens, C; Wentzensen, N; Whittemore, AS; Wilkens, LR; Winqvist, R; Wu, AH; Wu, X; Yang, HP; Zaffaroni, D; Pilar Zamora, M; Zheng, W; Ziogas, A; Chenevix-Trench, G; Pharoah, PD; Rookus, MA; Hooning, MJ; Goode, EL (2016-05)
      Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well ...
    • Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. 

      Hahne, JC; Valeri, N (2018)
      Non-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number ...